Skip to contentA
Agios Pharmaceuticals, Inc.
A
AGIOAgios Pharmaceuticals, Inc. Q3 2015 · 10-Q
Revenue$5.48M$5.48M−83.8% vs Q3 2014 Net Income-$40.26M-$40.26MN/M vs Q3 2014 EPS Diluted-$1.07-$1.07N/M vs Q3 2014 Operating Income-$40,475,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Agios Pharmaceuticals, Inc. · CIK 1439222 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$28,114,000N/M Margins · derivedOperating margin-738.6%−748.1 pt vs Q3 2014
Net margin-734.6%−745.5 pt vs Q3 2014
ended Sep 30, 2015 · filed Nov 6, 2015 · 37 d after period end